...
首页> 外文期刊>Journal of Pathology: Journal of the Pathological Society of Great Britain and Ireland >Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications.
【24h】

Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications.

机译:356淋巴结阴性乳腺癌中p53,c-erbB-2和拓扑异构酶IIα表达,DNA倍性,激素受体状态与增殖之间的相关性:对预后的影响。

获取原文
获取原文并翻译 | 示例
           

摘要

Various new prognostic indicators have been identified for mammary carcinomas, but the issue of their significance remains unsettled. The prognostic impact of p53, c-erbB-2, and topoisomerase II alpha expression was investigated in relation to standard prognostic factors for carcinomas of the breast and to the tumour cell growth fraction. Paraffin-embedded specimens of 356 node-negative infiltrating ductal carcinomas were stained immunohistochemically using a polyclonal antiserum to c-erbB-2, and the monoclonal antibodies DO-1 (p53), Ki-S4 (topoisomerase II alpha), and Ki-S5 (Ki-67). The patients were followed for a median duration of 99 months. Both p53 and c-erbB-2 were significantly associated with high tumour grade, large tumour size, DNA aneuploidy, lack of steroid hormone receptors, young age, and increased topoisomerase II alpha and Ki-67 expression levels. The correlation of p53 and c-erbB-2 was not significant. Topoisomerase II alpha and Ki-67 scores closely paralleled each other, indicating that both reflect the proliferative activity of tumour cells. A univariate analysis of overall (OS), specific (SS), and disease-free survival (DFS) revealed all the above-mentioned parameters to be statistically significant except patient age, which was relevant only to overall survival. Multivariate analysis with inclusion of all covariates selected tumour size and proliferation (topoisomerase II alpha and Ki-67) indices as independent predictors of survival in all three models. No additional information was gained by p53 or c-erbB-2. It is concluded that the proliferative activity, as assessed by topoisomerase II alpha or Ki-67 immunostaining, is the most useful indicator of breast cancer prognosis, except for tumour size.
机译:已经确定了各种新的乳腺癌预后指标,但是其重要性的问题尚未解决。研究了p53,c-erbB-2和拓扑异构酶IIα表达对乳腺癌的标准预后因素以及肿瘤细胞生长分数的预后影响。使用针对c-erbB-2的多克隆抗血清和单克隆抗体DO-1(p53),Ki-S4(拓扑异构酶II alpha)和Ki-S5免疫组化对356例淋巴结阴性浸润性导管癌的石蜡包埋标本进行免疫染色。 (纪67)。随访患者中位时间为99个月。 p53和c-erbB-2均与高肿瘤等级,大肿瘤大小,DNA非整倍性,缺乏类固醇激素受体,年轻年龄以及拓扑异构酶IIα和Ki-67表达水平升高显着相关。 p53和c-erbB-2的相关性不显着。拓扑异构酶II alpha和Ki-67得分彼此平行,表明二者均反映了肿瘤细胞的增殖活性。对总体(OS),特异性(SS)和无病生存(DFS)的单变量分析显示,除患者年龄外,上述所有参数均具有统计学意义,而年龄仅与总体生存有关。多变量分析,包括所有协变量,选择了肿瘤大小和增殖指数(拓扑异构酶II alpha和Ki-67)作为所有三个模型中生存的独立预测因子。 p53或c-erbB-2未获得其他信息。结论是,通过拓扑异构酶II alpha或Ki-67免疫染色评估的增殖活性是乳腺癌预后的最有用指标,除了肿瘤大小。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号